Weekly Research Analysts’ Ratings Updates for Ascendis Pharma A/S (ASND)

Several analysts have recently updated their ratings and price targets for Ascendis Pharma A/S (NASDAQ: ASND):

• 10/13/2026 – Ascendis Pharma A/S had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 10/10/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/26/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/25/2026 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $300.00 price target on the stock.
• 9/16/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by UBS Group AG. They now have a $344.00 price target on the stock.
• 9/15/2026 – Ascendis Pharma A/S was downgraded by Raymond James Financial, Inc. from “strong-buy” to “outperform”. They now have a $287.00 price target on the stock.
• 9/10/2026 – Ascendis Pharma A/S was given a new $344.00 price target by HC Wainwright.
• 9/10/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by TD Cowen.
• 9/10/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/1/2026 – Ascendis Pharma A/S had its price target raised by Oppenheimer Holdings, Inc. from $304.00 to $312.00. They now have an “outperform” rating on the stock.
• 9/1/2026 – Ascendis Pharma A/S had its price target lowered by Morgan Stanley from $275.00 to $273.00. They now have an “overweight” rating on the stock.
• 9/1/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Wedbush. They now have a $327.00 price target on the stock.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Jefferies Financial Group Inc. from $333.00 to $330.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Stifel Nicolaus from $328.00 to $326.00. They now have a “buy” rating on the stock.
• 8/31/2026 – Ascendis Pharma A/S was given a new $345.00 price target by UBS Group AG.
• 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Bank of America Corporation from $306.00 to $304.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Ascendis Pharma A/S is now covered by HC Wainwright. They set a “buy” rating and a $345.00 price target on the stock.
• 8/27/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by HC Wainwright. They now have a $345.00 price target on the stock.
• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/15/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean-Jacques Bienaimé bought 2,000 shares of the stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.